Vinge has advised Svea Bank AB (the “Company”) in connection with its issuance of additional tier 1…
Vinge has advised Scandic Hotels Group AB (publ) in connection with the entry into of a SEK 3,450,00…
Vinge has advised Danske Bank A/S, Danmark, Sverige Filial in connection with the signing of a new S…
Vinge has advised Sandvik AB (publ) and Sandvik Treasury AB (publ) in connection with the entry into…
The transaction closed on 30 November 2022.
The loan agreement with the European Investment Bank (EIB) grants Oncopeptides access to a renewed u…
Vinge has advised Luossavaara-Kiirunavaara AB (publ) (“LKAB”) in connection with its investment in,…
Vinge has advised Baseload Capital Holding AB in connection with a financing round of approximately…
The board of directors of Oncopeptides has resolved on a directed new issue of shares, whereby Oncop…
Vinge has advised Brunswick Real Estate Capital in connection with an approximately SEK 1.7 billion…
Vinge has advised the fintech company Credit Opportunity One AB (publ) (u.n.c.t. Moank Fintech Group…
Vinge has advised Skandinaviska Enskilda Banken AB (publ) as to Swedish law in connection with the i…
Vinge has advised Main Capital Partners and its portfolio company Björn Lundén with the acquisition…
Vinge has advised Swedbank AB (publ) in connection with an approximately SEK 1.5 billion credit faci…
Vinge has assisted Allianz Real Estate in connection with an investment of SEK 7.9 billion in Heimst…
Vinge has advised Randviken Fastigheter AB (publ) in connection with the acquisition and acquisition…
